- Home
- AKTX vs AQMS Comparison
AKTX vs AQMS Comparison
Compare AKTX & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- AQMS
- Stock Information
- Founded
- AKTX N/A
- AQMS 2014
- Country
- AKTX United States
- AQMS United States
- Employees
- AKTX N/A
- AQMS N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- AQMS Metal Fabrications
- Sector
- AKTX Health Care
- AQMS Industrials
- Exchange
- AKTX Nasdaq
- AQMS Nasdaq
- Market Cap
- AKTX 25.1M
- AQMS 24.2M
- IPO Year
- AKTX N/A
- AQMS 2015
- Fundamental
- Price
- AKTX $0.61
- AQMS $6.73
- Analyst Decision
- AKTX Strong Buy
- AQMS Buy
- Analyst Count
- AKTX 2
- AQMS 1
- Target Price
- AKTX $3.30
- AQMS $12.00
- AVG Volume (30 Days)
- AKTX 458.6K
- AQMS 3.4M
- Earning Date
- AKTX 11-14-2025
- AQMS 11-12-2025
- Dividend Yield
- AKTX N/A
- AQMS N/A
- EPS Growth
- AKTX N/A
- AQMS N/A
- EPS
- AKTX N/A
- AQMS N/A
- Revenue
- AKTX N/A
- AQMS N/A
- Revenue This Year
- AKTX N/A
- AQMS N/A
- Revenue Next Year
- AKTX N/A
- AQMS $550.00
- P/E Ratio
- AKTX N/A
- AQMS N/A
- Revenue Growth
- AKTX N/A
- AQMS N/A
- 52 Week Low
- AKTX $0.57
- AQMS $3.37
- 52 Week High
- AKTX $2.45
- AQMS $39.40
- Technical
- Relative Strength Index (RSI)
- AKTX 34.50
- AQMS 46.23
- Support Level
- AKTX $0.60
- AQMS $6.41
- Resistance Level
- AKTX $0.84
- AQMS $7.60
- Average True Range (ATR)
- AKTX 0.06
- AQMS 1.23
- MACD
- AKTX -0.01
- AQMS -0.45
- Stochastic Oscillator
- AKTX 2.29
- AQMS 7.69
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.